Thyrocare Strengthens Growth Story with Strong Q4 Performance and New Genomics Expansion

Thyrocare Technologies has reported a strong finish to FY26, driven by rapid expansion in specialty diagnostics, operational efficiency, and its strategic push into genomics. The company posted a 128 percent year-on-year jump in Profit After Tax (PAT) during Q4FY26, reflecting growing demand for advanced diagnostic services across India.

The diagnostics major recorded consolidated revenue of ₹223.95 crore in the quarter, marking a 20 percent increase compared to the same period last year. EBITDA grew 31 percent year-on-year to ₹75.09 crore, while test volumes surged 29 percent to 59 million tests, reinforcing Thyrocare’s leadership in high-volume diagnostics.

A key growth driver for the company has been the expansion of its specialty diagnostics portfolio. Thyrocare has significantly strengthened its offerings in allergy testing with more than 250 SKUs on the Phadia platform and has now entered the genomics segment with a new state-of-the-art genomics laboratory in Navi Mumbai.

The newly launched genomics lab is expected to enhance access to precision diagnostics and predictive healthcare solutions in India. The facility will support advanced genomics-based testing services, including Non-invasive Prenatal Testing (NIPT) through Thyrocare’s HerCheck platform, while also enabling high-throughput genomic analysis.

Commenting on the expansion, Rahul Guha, MD & CEO of Thyrocare Technologies, stated that genomics will play an increasingly critical role as healthcare shifts toward predictive and preventive care models. He emphasized the company’s focus on making advanced genomics testing affordable and accessible at scale.

Dr. Ramesh Kinha, COO of Thyrocare, highlighted that the genomics lab combines Thyrocare’s automation-driven infrastructure and nationwide diagnostic network to deliver reliable and high-quality specialty testing across the country.

Operationally, Thyrocare also continued to improve efficiency metrics during the quarter. The company reduced complaints per million tests by 34 percent year-on-year and achieved an average turnaround time of 3.43 hours from sample receipt, positioning itself among India’s fastest diagnostic chains.

For the full FY26 financial year, Thyrocare reported consolidated revenue growth of 21 percent to ₹829.04 crore, while PAT increased 81 percent to ₹162.85 crore. The company processed 209.6 million tests during the year, supported by strong growth in both franchise and partnership networks.

The combination of robust financial performance and investments in genomics and specialty diagnostics signals Thyrocare’s broader strategy to strengthen its position in India’s evolving preventive and precision healthcare market.

Source: https://www.bwhealthcareworld.com/article/thyrocare-q4-profit-jumps-128-as-specialty-diagnostics-expands-605859